•  
  •  

Home > MJM > Vol. 6 (2020) > Iss. 3

 

Author Credentials

Ibrahim Mohammed BS Cherishma Nagisetty BS Arslan Iqbal MD Michael Abdelmasseh MD Doreen Griswold MD Muhammad Omer Jamil MD Juan R. Sanabria MD

Loading...

Media is loading
 

DOI

10.33470/2379-9536.1259

Abstract

Background. Gastric cancer has a low overall survival rate worldwide, and surgery still remains the intent to cure option on early stages of disease. HER-2 positive cancers may have a survival advantage. We present a patient with stage IV gastric cancer HER-2 positive responsive to Herceptin, free of detectable disease two years after surgery.

Patient Presentation. 70 years old Caucasian male complained of left-sided chest pain. Upon evaluation, he was diagnosed with HER-2 positive adenocarcinoma of the stomach at the pylorus with two liver metastases. Near complete response was observed with Herceptin and Cis-platinum based chemotherapy followed by 80% distal gastrectomy and liver resection with uneventful recovery. Two years follow up reported a patient living normal life with undetectable disease.

Conclusion. Multimodality targeted therapy may accomplish 24months cure of advanced malignant gastric disease.

Conflict(s) of Interest

The authors have no financial disclosures to declare and no conflicts of interest to report.

Download

Share

COinS